Literature DB >> 33755494

Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials: A Systematic Review and Meta-Analysis.

Peter J Godolphin1,2, Philip M Bath2, Ale Algra3,4, Eivind Berge5, Martin M Brown6, John Chalmers7, Lelia Duley1, Misha Eliasziw8, John Gregson9, Jacoba P Greving4, Graeme J Hankey10, Naohisa Hosomi11, S Claiborne Johnston12, Emily Patsko13, Annamarei Ranta14, Per Morten Sandset15, Joaquín Serena16, Christian Weimar17, Alan A Montgomery1.   

Abstract

Background and Purpose- In randomized stroke trials, central adjudication of a trial's primary outcome is regularly implemented. However, recent evidence questions the importance of central adjudication in randomized trials. The aim of this review was to compare outcomes assessed by central adjudicators with outcomes assessed by site investigators. Methods- We included randomized stroke trials where the primary outcome had undergone an assessment by site investigators and central adjudicators. We searched MEDLINE, EMBASE, CENTRAL (Cochrane Central Register of Controlled Trials), Web of Science, PsycINFO, and Google Scholar for eligible studies. We extracted information about the adjudication process as well as the treatment effect for the primary outcome, assessed both by central adjudicators and by site investigators. We calculated the ratio of these treatment effects so that a ratio of these treatment effects >1 indicated that central adjudication resulted in a more beneficial treatment effect than assessment by the site investigator. A random-effects meta-analysis model was fitted to estimate a pooled effect. Results- Fifteen trials, comprising 69 560 participants, were included. The primary outcomes included were stroke (8/15, 53%), a composite event including stroke (6/15, 40%) and functional outcome after stroke measured on the modified Rankin Scale (1/15, 7%). The majority of site investigators were blind to treatment allocation (9/15, 60%). On average, there was no difference in treatment effect estimates based on data from central adjudicators and site investigators (pooled ratio of these treatment effects=1.02; 95% CI, [0.95-1.09]). Conclusions- We found no evidence that central adjudication of the primary outcome in stroke trials had any impact on trial conclusions. This suggests that potential advantages of central adjudication may not outweigh cost and time disadvantages in stroke studies if the primary purpose of adjudication is to ensure validity of trial findings.

Entities:  

Keywords:  adjudication; clinical trial; meta-analysis; stroke; systematic review

Year:  2019        PMID: 33755494     DOI: 10.1161/STROKEAHA.119.025019

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  3 in total

1.  Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial.

Authors:  Pierre Amarenco; Hans Denison; Scott R Evans; Anders Himmelmann; Stefan James; Mikael Knutsson; Per Ladenvall; Carlos A Molina; Yongjun Wang; S Claiborne Johnston
Journal:  JAMA Neurol       Date:  2020-11-07       Impact factor: 18.302

2.  Added Value of a Blinded Outcome Adjudication Committee in an Open-Label Randomized Stroke Trial.

Authors:  Nadinda A M van der Ende; Bob Roozenbeek; Olvert A Berkhemer; Peter J Koudstaal; Jelis Boiten; Ewoud J van Dijk; Yvo B W E M Roos; Robert J van Oostenbrugge; Charles B L M Majoie; Wim van Zwam; Hester F Lingsma; Aad van der Lugt; Diederik W J Dippel
Journal:  Stroke       Date:  2021-10-05       Impact factor: 7.914

3.  Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.

Authors:  S Claiborne Johnston; Pierre Amarenco; Maria Aunes; Hans Denison; Scott R Evans; Anders Himmelmann; Marianne Jahreskog; Stefan James; Mikael Knutsson; Per Ladenvall; Carlos A Molina; Sven Nylander; Joachim Röther; Yongjun Wang
Journal:  Stroke       Date:  2021-09-03       Impact factor: 7.914

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.